Comparison of lionheart LVAD-implanted calves based on renal infarctions

John M. Connell, Walter Pae, Gerson Rosenberg

Research output: Contribution to journalArticle

Abstract

Calves implanted with the LionHeart left ventricular assist device during the Food and Drug Administration Investigational Device Exemption (IDE) trial had fewer renal infarctions than calves implanted after this trial (post-IDE). Since a decrease in renal infarctions indicates a favorable outcome, we compared nine IDE with 16 post-IDE implantations. Renal infarct severity was graded (0 to 4) on the basis of necropsy reports, histopathology reports, and photographs. Implants were compared for duration of support, anticoagulation, device flow, percent fill, device rate, free plasma hemoglobin, fibrinogen, platelet count, nonsteroidal anti-inflammatory drug use, inlet cannula shape, and outlet graft-to-graft anastomosis technique. IDE calves had lower renal pathology scores (1.8 vs. 2.8, p = 0.03), mean device percent fill (88.5% vs. 94.0%, p = 1 × 10), and median free plasma hemoglobin (2.6 vs. 4.4 mg/dL, p = 0.01). IDE animals also had a higher mean device rate (108 vs. 98 bpm, p = 0.04), received low-molecular-weight dextran in the early postoperative period, began oral warfarin earlier, had straighter inlet cannulae, and had factory-sewn outlet graft-to-graft anastomoses. Duration of support did not predict severity of renal infarction, and there were no differences in device flow, international normalized ratio, platelet count, or nonsteroidal anti-inflammatory drug use. These results could assist future implantations.

Original languageEnglish (US)
Pages (from-to)147-151
Number of pages5
JournalASAIO Journal
Volume53
Issue number2
DOIs
StatePublished - Mar 1 2007

Fingerprint

Grafts
Infarction
Kidney
Equipment and Supplies
Hemoglobin
Platelets
Hemoglobins
Anti-Inflammatory Agents
Left ventricular assist devices
Investigational Drugs
Plasmas
Dextran
Pathology
Warfarin
Dextrans
Transplants
Pharmaceutical Preparations
Fibrinogen
Industrial plants
Animals

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Biomedical Engineering

Cite this

@article{969786c2ae744854b63ad7a8d2cd2e49,
title = "Comparison of lionheart LVAD-implanted calves based on renal infarctions",
abstract = "Calves implanted with the LionHeart left ventricular assist device during the Food and Drug Administration Investigational Device Exemption (IDE) trial had fewer renal infarctions than calves implanted after this trial (post-IDE). Since a decrease in renal infarctions indicates a favorable outcome, we compared nine IDE with 16 post-IDE implantations. Renal infarct severity was graded (0 to 4) on the basis of necropsy reports, histopathology reports, and photographs. Implants were compared for duration of support, anticoagulation, device flow, percent fill, device rate, free plasma hemoglobin, fibrinogen, platelet count, nonsteroidal anti-inflammatory drug use, inlet cannula shape, and outlet graft-to-graft anastomosis technique. IDE calves had lower renal pathology scores (1.8 vs. 2.8, p = 0.03), mean device percent fill (88.5{\%} vs. 94.0{\%}, p = 1 × 10), and median free plasma hemoglobin (2.6 vs. 4.4 mg/dL, p = 0.01). IDE animals also had a higher mean device rate (108 vs. 98 bpm, p = 0.04), received low-molecular-weight dextran in the early postoperative period, began oral warfarin earlier, had straighter inlet cannulae, and had factory-sewn outlet graft-to-graft anastomoses. Duration of support did not predict severity of renal infarction, and there were no differences in device flow, international normalized ratio, platelet count, or nonsteroidal anti-inflammatory drug use. These results could assist future implantations.",
author = "Connell, {John M.} and Walter Pae and Gerson Rosenberg",
year = "2007",
month = "3",
day = "1",
doi = "10.1097/MAT.0b013e31802deb58",
language = "English (US)",
volume = "53",
pages = "147--151",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Comparison of lionheart LVAD-implanted calves based on renal infarctions. / Connell, John M.; Pae, Walter; Rosenberg, Gerson.

In: ASAIO Journal, Vol. 53, No. 2, 01.03.2007, p. 147-151.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of lionheart LVAD-implanted calves based on renal infarctions

AU - Connell, John M.

AU - Pae, Walter

AU - Rosenberg, Gerson

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Calves implanted with the LionHeart left ventricular assist device during the Food and Drug Administration Investigational Device Exemption (IDE) trial had fewer renal infarctions than calves implanted after this trial (post-IDE). Since a decrease in renal infarctions indicates a favorable outcome, we compared nine IDE with 16 post-IDE implantations. Renal infarct severity was graded (0 to 4) on the basis of necropsy reports, histopathology reports, and photographs. Implants were compared for duration of support, anticoagulation, device flow, percent fill, device rate, free plasma hemoglobin, fibrinogen, platelet count, nonsteroidal anti-inflammatory drug use, inlet cannula shape, and outlet graft-to-graft anastomosis technique. IDE calves had lower renal pathology scores (1.8 vs. 2.8, p = 0.03), mean device percent fill (88.5% vs. 94.0%, p = 1 × 10), and median free plasma hemoglobin (2.6 vs. 4.4 mg/dL, p = 0.01). IDE animals also had a higher mean device rate (108 vs. 98 bpm, p = 0.04), received low-molecular-weight dextran in the early postoperative period, began oral warfarin earlier, had straighter inlet cannulae, and had factory-sewn outlet graft-to-graft anastomoses. Duration of support did not predict severity of renal infarction, and there were no differences in device flow, international normalized ratio, platelet count, or nonsteroidal anti-inflammatory drug use. These results could assist future implantations.

AB - Calves implanted with the LionHeart left ventricular assist device during the Food and Drug Administration Investigational Device Exemption (IDE) trial had fewer renal infarctions than calves implanted after this trial (post-IDE). Since a decrease in renal infarctions indicates a favorable outcome, we compared nine IDE with 16 post-IDE implantations. Renal infarct severity was graded (0 to 4) on the basis of necropsy reports, histopathology reports, and photographs. Implants were compared for duration of support, anticoagulation, device flow, percent fill, device rate, free plasma hemoglobin, fibrinogen, platelet count, nonsteroidal anti-inflammatory drug use, inlet cannula shape, and outlet graft-to-graft anastomosis technique. IDE calves had lower renal pathology scores (1.8 vs. 2.8, p = 0.03), mean device percent fill (88.5% vs. 94.0%, p = 1 × 10), and median free plasma hemoglobin (2.6 vs. 4.4 mg/dL, p = 0.01). IDE animals also had a higher mean device rate (108 vs. 98 bpm, p = 0.04), received low-molecular-weight dextran in the early postoperative period, began oral warfarin earlier, had straighter inlet cannulae, and had factory-sewn outlet graft-to-graft anastomoses. Duration of support did not predict severity of renal infarction, and there were no differences in device flow, international normalized ratio, platelet count, or nonsteroidal anti-inflammatory drug use. These results could assist future implantations.

UR - http://www.scopus.com/inward/record.url?scp=34247269640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247269640&partnerID=8YFLogxK

U2 - 10.1097/MAT.0b013e31802deb58

DO - 10.1097/MAT.0b013e31802deb58

M3 - Article

VL - 53

SP - 147

EP - 151

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 2

ER -